Navigation Links
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
Date:6/28/2008

ing the receptor pharmacology data entitled "Improved Dihydroergotamine (DHE) Pharmacology Following Orally-Inhaled Delivery." In addition to this study, the Company presented five posters relating to the MAP0004 program, including:

-- Newer Acute Migraine Specific Drugs May Provide Improved Sustained Relief and Freedom Over 24 and 48 Hours Post Dosing

-- Chronic Inhalation Toxicological Assessment of Dihydroergotamine in Dogs

-- Assessment of QTc Effect of DHE When Delivered Via the Lung by the Tempo Inhaler

-- MAP0004, an Orally Inhaled Formulation of DHE, Delivers Faster and More Consistent Blood Levels of the Drug Compared to Traditional Oral, Subcutaneous, Intramuscular, and Intranasal Formulations of DHE

-- Systemic Pharmacokinetics of DHE When Delivered Via the Lung to Asthmatics by the Tempo Inhaler

About MAP0004

MAP0004 is a proprietary orally inhaled version of dihydroergotamine, or DHE, intended to treat migraine. In the Company's Phase 2 efficacy study, MAP0004 provided pain relief as early as within ten minutes of dosing, and this relief was sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia. Based on these results, as well as independent research that concludes that patients prefer migraine therapies providing fast onset, pain relief, sustained pain relief and safety, the Company believes that MAP0004 has the potential to be a first-line therapy for migraine patients. Historically, estimated onset of significant pain relief with oral triptans, the class of drugs most often prescribed for treating migraine, occurs between 45 and 90 minutes after dosing. In 2007, triptans generated sales of approximately $2.2 billion in the United States, according to data published by IMS Health.

MAP0004 is designed to be an easy to use, non-invasive, at-home therapy that patients self-administer using the Company's proprietary hand-held
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
6. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
7. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
8. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... we bring you a special edition of #MedicareMonday on Medicare,s 50 th anniversary. ... Medicare resources and continue highlighting the success of the prescription drug benefit, commonly referred ... out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... Calif. , July 30, 2015  Amgen (NASDAQ: ... , partner and managing director of Warburg Pincus LLC, to ... pleased to welcome Fred Hassan and the deep, ... Amgen Board," said Robert A. Bradway , chairman and ... commitment to innovation will serve Amgen well." Mr. ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... Oct. 14, 2011 Pregis Corporation, a leading ... products and specialty packaging solutions, announced today that ... to sell its Kobusch-Sengewald business unit to Sun ... adviser to Sun Capital Partners, Inc., for gross ...
... ACCESS PHARMACEUTICALS, INC. ... drug-delivery platforms to develop treatments in areas of oncology, ... its MuGard website to include a clinical ... and seasoned oncology nurse practitioner,s experience with oral ...
Cached Medicine Technology:Pregis Announces Sale of Kobusch-Sengewald Business to an Affiliate of Sun European Partners 2Pregis Announces Sale of Kobusch-Sengewald Business to an Affiliate of Sun European Partners 3Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage 2Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage 3
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... industry players to know in predictive health analytics , Jvion continues to ... The firm creates predictive software that targets patient and population level illness to ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... There’s ... as possible, even when it comes time to cook the next meal, making July ... of July by practicing best grilling tips and recipes. , Make the next cookout ...
(Date:7/31/2015)... ... 31, 2015 , ... Facebook, Twitter, Linkedin and blogs are ... media profiles to better connect with the public. The agency website at ... insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide effortless ways ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2
... EAST LANSING, Mich. Scientists at Michigan State University ... that trigger inflammation in the mammary gland. ... increasing the risk of breast cancer. Progesterone is ... the normal mammary gland. Progesterone previously has been identified ...
... 19, 2009) Scientists from the U.S. Department of ... Chicago,s Brain Tumor Center have developed a way to ... nanoparticles bonded to soft biological material. Thousands of ... the tumors are resistant to conventional therapies. This nano-bio ...
... , , TAMPA, Fla., Aug. ... People for the Ethical Treatment of Animals (PETA) to immediately end ... image and portrayal of obese/overweight individuals. The OAC believes this campaign ... their size or weight. , , The campaign ...
... , WASHINGTON, Aug. 19 Following ... , , The "Bulletin," which is free of ... you the latest issues and news affecting people with disabilities. To ... on "Online mailing list archives," select "NCD-NEWS-L," click on "Join or ...
... ... part of the new series of standard hybrid stepper motors presented by NMB. These popular ... ... announced today the availability of a new line of standard hybrid stepper motors. , , ...
... , , PACE(R) Programs Open Doors ... WASHINGTON, Aug. 19 In celebration of National Senior ... working with many of the individual Programs of All-inclusive Care for ... about PACE through health fairs and open houses. Designed to ...
Cached Medicine News:Health News:MSU scientists: Progesterone leads to inflammation 2Health News:Argonne, University of Chicago scientists develop targeted cancer treatment using nanomaterials 2Health News:Obesity Action Coalition Calls on PETA to Immediately End Campaign Stigmatizing Overweight and Obese Individuals 2Health News:National Council on Disability Monthly Bulletin for August 2009 2Health News:National Council on Disability Monthly Bulletin for August 2009 3Health News:National Council on Disability Monthly Bulletin for August 2009 4Health News:National Council on Disability Monthly Bulletin for August 2009 5Health News:National Council on Disability Monthly Bulletin for August 2009 6Health News:National Council on Disability Monthly Bulletin for August 2009 7Health News:NMB's New Series of Standard Hybrid Stepper Motors Now Available 2Health News:National Senior Citizens Day Celebrated August 21 Amid Health Care Reform Debate 2Health News:National Senior Citizens Day Celebrated August 21 Amid Health Care Reform Debate 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: